PubNub Introduces Blocks.ai: The Control Plane and Network Layer For AI Agents
8.7.2026 14:00:00 CEST | Business Wire | Press Release
PubNub introduces Blocks.ai today, a global network to connect and control agents across all agent frameworks, providers, and APIs. Blocks.ai lets developers reach their existing AI agents regardless of where they are hosted. Blocks Network supports all AI agent use cases without opening inbound ports, setting up tunnels, changing DNS, or modifying firewall rules. For more than a decade, PubNub has been the infrastructure and platform for real-time connectivity supporting billions of devices, now, PubNub delivers Blocks Network connecting the Internet of Agents.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708521206/en/
AI agents have become increasingly critical to businesses who want control over their models, code, and data. But once those agents are running locally or behind a firewall, making them reachable from custom frontends can require brittle infrastructure work. This is a key reason why McKinsey estimates that fewer than 10% of enterprise agents have ever reached production. Blocks Network is designed to remove that barrier while keeping the agent private and under the builder’s control.
Blocks Network works in both directions. Developers who don't run an agent of their own can still draw on Blocks Network: any application, web app, backend service, or mobile app, can discover capability-specific agents on the network and call them with a few lines of code using the open-source SDKs. Instead of managing a different API key for every provider, and building a new integration for each capability, a developer adds AI functionality in the way they'd call any function. The agents behind those capabilities keep running wherever their builders host them.
“You can build a great agent in an afternoon, but it often just sits there, isolated on your machine,” said Todd Greene, CEO of PubNub. “With Blocks, build an agent, connect it once, and it’s available to any frontend, application, or user who needs it. Blocks Network is the global agent control plane to connect, call, and share efficiencies without rebuilding anything.”
Connecting Agents to Specialist Capabilities
Blocks.ai not only unleashes agent connections, it also connects agents to other agents’ capabilities previously blocked off by frameworks and walled gardens. The same connection that makes an agent reachable also lets it call other agents on the Blocks Network regardless of framework. Once connected, a builder’s agent can access discoverable capabilities such as code review, transcription, PDF and QR generation, data extraction, streaming compute, and more, without building and maintaining separate integrations for each one.
Built for Control, Privacy, and No Lock-In
Blocks.ai is built on PubNub’s real-time backbone, with zero-trust security, a 99.999% SLA, SOC 2, and GDPR compliance, delivering agent control and connectivity in any environment. Open-source SDKs for TypeScript and Python are available under the Apache-2.0 license, making them auditable and easy to integrate.
“What makes this resonate with businesses is that nothing about it asks them to give up control,” said Greene. "Your agent stays on your machine and your data stays yours, yet you can reach it from anywhere, let it call other agents on the network, and share it so your customers and partners can call it too. It's open, it's auditable, it's secure, and it doesn't lock you into anyone's stack, including ours.
“This launch marks a natural evolution for PubNub,” Todd continued, “which powers real-time connectivity for billions of devices every day. With Blocks.ai, the company is applying that same network to a new class of endpoint: AI agents that need to be reachable, connected, and secure wherever they run."
Generally Available
Blocks.ai is available to connect today. Anyone can connect AI agents and make them globally callable in seconds using the open-source TypeScript and Python SDKs or the CLI.
Explore documentation for Blocks: https://blocks.ai/docs.
About PubNub
PubNub is a real-time control plane and interactivity platform for connecting humans, devices, and now, with Blocks.ai, AI agents. Enabling teams to focus on launching features rather than managing infrastructure, PubNub delivers global pub/sub-messaging, <100ms latency worldwide, backed by a 99.999% SLA and zero-trust security. Trusted by over 2,000 companies - including DAZN, Zillow, Docusign, Beamable, and the American Cancer Society - PubNub powers more than 3 trillion API transactions every month. Start building today at pubnub.com or blocks.ai.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260708521206/en/
Contacts
Media Contact
Kayley Smith
Director, Marketing and Public Relations
kayley.smith@pubnub.com
+1 737-328-9825
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Randomized Controlled Trial Shows Promise of a Ketogenic Diet in Psychotic Disorders8.7.2026 15:00:00 CEST | Press Release
Published today in Schizophrenia Bulletin, a first-of-its-kind randomized controlled trial (RCT) from researchers at the University of California, San Francisco (UCSF), and funded in part by the National Institute of Mental Health (NIMH), adds to growing literature on the potential benefit of a ketogenic diet for treating psychotic disorders. The study, which enrolled participants with schizophrenia-spectrum or bipolar-1 disorders, demonstrated rapid metabolic improvements with a ketogenic diet compared to diet-as-usual during an initial one-month RCT open-label phase. Furthermore, those who continued with the optional four-month single-arm ketogenic diet extension saw meaningful gains across metabolic, psychiatric, and cognitive measures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618626815/en/ First Randomized Controlled Trial Shows Promise of a Ketogenic Diet in Psychotic Disorders Of the 58 participants enrolled,
Teamily AI Publicly Launches Human+AI Social Platform to Make Building and Growing a Company Easy for Every Team8.7.2026 15:00:00 CEST | Press Release
Teamily AI (https://Teamily.ai), together with its Agentic AI Infra platform TensorOpera AI (https://TensorOpera.ai), today announced the public launch of its Human+AI social platform, a product stack that has already served more than 5 million users around the world. Starting today in Palo Alto and rolling out simultaneously across dozens of countries, this first public launch opens the full stack to everyone with a single mission: to make building and growing a company easy for every person and every team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708584390/en/ "This is the moment we open our doors to the world," said co-founders Dr. Aiden Chaoyang He and Professor Salman Avestimehr. "We want every person and every team to be able to move from idea to product, from product to market, and from market to growth and investment, with an AI-native team by their side." At its core, Teamily AI enables humans and AI agents
Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform8.7.2026 14:30:00 CEST | Press Release
Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. Leading cancer institutions are already adopting the upright approach. Stanford Medicine delivered the world’s first compact upright proton therapy treatment on 4 June 2026. Dana-Farber Cancer Institute and McLaren Health Care are among the institutions bringing the upright platform into their programmes — adoption that spans world-leading academic centers and smaller, regional community-based networks alike. The financing will scale manufacturing and accelerate commercial deployment, and continue clinical and product development across Leo Cancer Care’s integrated u
LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development8.7.2026 14:00:00 CEST | Press Release
The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/ LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC and AI development IQM Halocene H4 is the first and most advanced on-premises superconducting quantum computer of its kind, combining quantum error correction with NISQ qubits. The system will be delivered in 2027, followed by a series of upgrades delivered in multiple phases with an increasing number of logical qubits. The IQM Halocene H4 and the upgraded systems will enable LUMI consortium users, for the first time, to develop and implement Quantum Error Correction (QEC) concepts on a world-leadi
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations8.7.2026 14:00:00 CEST | Press Release
Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manifestations, often associated with substantial physical and psychosocial burden, the lack of targeted treatment makes the disease hard to control,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “This Breakthrough Therapy designation demonstrates that enpatoran has the potential to redefine how we approach lupus, by addressing the visible burden of rash, while potentially driving benefit beyond the skin. We look forward to working with the FDA to potentially bring this much-needed option to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom